CHeT Analytics
CHeT Analytics is developing strategies to reduce drug development costs and enhance clinical care for those living with neurological disorders. By leveraging one of the world’s largest repositories of clinical trial data for Parkinson’s and Huntington’s diseases, new insights are being made possible through predictive modeling and simulation.
- Access to clinical trial and observational study data from over 100 studies
- Extensive Knowledge in developing clinical disease progression models of neurological disorders
Data Modeling and Simulation
We can utilize our expertise in statistical methodology and machine learning to provide analytical modeling, consulting and support to:
- Develop clinical disease progression models that predict meaningful clinical outcomes to patients, caregivers, and researchers
- Develop strategies to reduce drug development costs through efficient clinical trial designs
- Visualize complex data to identify patterns and drive strategic analysis
- Harmonize distinct sources of data to increase sample size and generate more robust findings
The Analytics Unit is developing tools for patients, clinicians, and caregivers to interact with the prediction models to help manage their disease in a data-driven manner. We believe creating such tools empowers patients and allows the entire care team to proactively plan for future scenarios that are based on real patients’ data of similar profiles. We specialize in drug development rescue re-analysis. Our modeling and simulation methods are able to identify sub-populations of treatment responders and exposure-response relationships, if any such exist, through post-hoc analyses.
Ancillary Analytical Services
Understanding every trial has unique needs, CHeT maximizes effectiveness with experienced resources to deliver customized biostatistics and data mining efforts. Explore how our team has driven impactful results across various studies, offering advanced data solutions and insights for clinical research. Check out our Case Studies to learn more about our methods, achievements, and contributions to the field.
Analytical Services - Pharmacology
To provide pre-clinical and clinical pharmacology expertise to guide drug development
- Develop protocols for pre-clinical and clinical testing of small molecule compounds and protein-based therapeutics
- Conduct pharmacokinetics and pharmacodynamics modeling and simulation throughout all phases of drug development
- Analyze pharmacology data to understand patient factors influencing drug exposure and response
- Conduct drug-drug interaction studies and concomitant medication monitoring to ensure optimal safety of experimental therapeutics
Biostatistical Services
Provide Biostatistical Support for New Studies
Knowledgeable in study processes from the planning phase to presentation of results (includes clinical trials, other interventional studies, and observational studies).
- Contribute to protocol development
- Develop a statistical analysis plan
- Provide Data Safety Monitoring Board support (i.e. unblinded statistician)
- Perform statistical analyses
- Promote standardized data collection based on CDISC standards
- Contribute to preparation of manuscripts
Provide Consulting
To assess relevant existing studies to answer research questions
- Develop and evaluate new outcome measures to quantify disease progression (e.g. composite scores)
- Utilize lab data and biospecimens to identify potential biomarkers to quantify disease progression
- Provide replication of analyses in independent studies as well as new exploratory analyses on existing study data
Frequently Asked Questions
Peggy Auinger, (M.S.) is a statistician with expertise in statistical and methodological aspects of clinical research. She works with many of the 100+ clinical trials and observational studies that CHeT Analytics manages and is very proficient with the databases. She also serves as the statistician on active studies, writing and reviewing the study protocol and the statistical analysis plan; performing statistical analyses; and working with the Safety Monitoring Committee. She is meticulous in study development, execution, and analysis, working to ensure rigor in study design, conduct, and presentation of results.